Filing Summary: Macandrews & Forbes Inc Just Disclosed New Siga Technologies Inc Position

Filing Summary: Macandrews & Forbes Inc Just Disclosed New Siga Technologies Inc Position

The New Macandrews & Forbes Inc Holding in Siga Technologies Inc

Macandrews & Forbes Inc filed with the SEC SC 13D/A form for Siga Technologies Inc. The form can be accessed here: 000156761916003230. As reported in Macandrews & Forbes Inc’s form, the filler as of late owns 30.8% or 24,156,358 shares of the Health Care–company.

Siga Technologies Inc stake is a new one for the and it was filed because of activity on November 16, 2016. We feel this shows Macandrews & Forbes Inc’s positive view for the stock.

Business Profile

SIGA Technologies, Inc. (SIGA) is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is Tecovirimat, also known as ST-246, an orally administered antiviral drug that targets orthopoxviruses. Tecovirimat is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). Tecovirimat is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. Tecovirimat has Orphan Drug designation for both the treatment and prevention of smallpox, and the treatment of orthopoxvirus infections (vaccinia, variola, monkeypox and cowpox). The Company uses contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture Tecovirimat. The Company also has a lead pre-clinical drug candidate with activity against approximately four serotypes of the dengue virus.

SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.

The stock decreased 2.04% or $0.05 on November 18, hitting $2.4. About 96,624 shares traded hands or 27.29% up from the average. SIGA Technologies, Inc. (OTCMKTS:SIGA) has risen 122.73% since April 18, 2016 and is uptrending. It has outperformed by 118.30% the S&P500.

SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The company has a market cap of $130.28 million. The Company’s lead product is Tecovirimat, also known as ST-246, an orally administered antiviral drug that targets orthopoxviruses. It currently has negative earnings. Tecovirimat is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield).

More recent SIGA Technologies, Inc. (OTCMKTS:SIGA) news were published by: Streetinsider.com which released: “Form 4 SIGA TECHNOLOGIES INC For: Nov 16 Filed by: KINDLER JEFFREY B” on November 18, 2016. Also Law360.com published the news titled: “Lessons From SIGA Technologies V. PharmAthene” on October 08, 2013. Streetinsider.com‘s news article titled: “SIGA Technologies (SIGA) Announces Completion of $35.3M Rights Offering” with publication date: November 16, 2016 was also an interesting one.

According to Zacks Investment Research, “SIGA Technologies Inc. is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents and vaccines to fight potential biowarfare pathogens. With broad technology platforms in both vaccines and antibiotics, SIGA’s product development programs emphasize the increasingly serious problem of drug resistant bacteria. In addition to smallpox, SIGA has antiviral programs targeting other Category A pathogens, including arenaviruses, dengue virus, and the filoviruses.”

SIGA Company Profile

SIGA Technologies, Inc. (SIGA), incorporated on December 28, 1995, is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is Tecovirimat, also known as ST-246, an orally administered antiviral drug that targets orthopoxviruses. Tecovirimat is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). Tecovirimat is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment